Search clinical trials for: Chronic- PF-06480605 150 mg SC Q4W

Total 74 results

Hoffmann-La Roche
Pfizer

Completed

A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Severe Ulcerative Colitis

Moderate to Severe Ulcerative Colitis

United States, Australia, Thailand, Poland, Russian Federation, Japan, Colombia, Spain, Turkey, Romania, India, Slovakia, France, Hungary, South Africa, Belgium, Bulgaria, Germany, Italy, Mexico, Serbia, Ukraine, United Kingdom
Shanghai JMT-Bio Inc.

Completed

Efficacy and Safety of JMT103 in Patients With Bone Metastases From Solid Tumors

Bone Metastases From Solid Tumors

China
R-Pharm International, LLC
IQVIA Pvt. Ltd; OCT Clinical Trials

Completed

Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis (CREDO 4)

Rheumatoid Arthritis

Korea, Republic of, United States, Germany, Hungary, Bulgaria, Poland, Taiwan, Mexico, Czechia, Argentina, United Kingdom, Belarus, Brazil, Colombia, Estonia, Latvia, Lithuania, Russian Federation
Bausch Health Americas, Inc.

Completed

Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 827

Psoriasis
Bill & Melinda Gates Medical Research Institute

Not yet recruiting

Study To Evaluate Safety, Tolerability, and Pharmacokinetics of MAM01 in African Population

Healthy Volunteers

Kenya, Uganda
Pfizer

Completed

Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus

Diabetes Melliuts, Type 2

United States
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Crohn's Disease | Colitis | Inflammatory Bowel Disease | IBD

United States, France, Poland, United Kingdom, Germany, Spain, Israel, Bulgaria, Serbia, South Africa, Japan, Canada, Australia, Netherlands, Korea, Republic of, Belgium, New Zealand, Brazil, Russian Federation, Austria, Hungary, ... and more
Pfizer

Completed

A Study To Observe Safety And Concentrations Of PF-05297909 And Proteins In Both Blood And Cerebrospinal Fluid After A Single Dose Of PF-05297909 In Healthy Adults

Healthy

United States
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Secukinumab in Japanese Patients With Active Ankylosing Spondylitis

Ankylosing Spondylitis

Japan
Bausch Health Americas, Inc.

Completed

(C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients With Rheumatoid Arthritis

Rheumatoid Arthritis

United States
Pfizer

Completed

A Study To Investigate How The Body Handles Multiple Doses Of PF-0243873 And To Investigate The Effect Of PF-02413873 On Sex Hormone Levels In Healthy Young Women

Endometriosis

United States, Belgium
Pfizer

Completed

A Study To Observe Safety And Blood Concentrations Of PF-04995274 During And Following the Administration of Multiple Doses Of PF-04995274 In Healthy Adult And Healthy Elderly Volunteers.

Healthy

United States
Pfizer

Completed

Study To Evaluate Safety, Tolerability, And Pharmacokinetics Of PF-06473871 In Normal Healthy Adults

Healthy

Belgium
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Recruiting

Evaluation of 611 in Chinese Adults With Moderate to Severe Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

China
Pfizer

Withdrawn

A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis

Ulcerative Colitis

United States
Bausch Health Americas, Inc.

Completed

Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Psoriasis

Psoriasis
Pfizer

Terminated

Multiple Dose Study Of PF-05231023 In Obese Adult Subjects

Type 2 Diabetes Mellitus (T2DM)

United States
Pfizer

Completed

STUDY TO COMPARE PHARMACOKINETICS (PK) OF SINGLE ORAL DOSES OF DIFFERENT PF-06882961 FORMULATIONS IN PARTICIPANTS WHO ARE OVERWEIGHT OR HAVE OBESITY

Overweight and/or Obesity

Belgium
Pfizer

Completed

Study To Characterize Mass Balance, Absolute Bioavailability, Fraction Absorbed And Pharmacokinetics Of 14C PF-06882961

Healthy Volunteer

Netherlands
Pfizer

Completed

A Study To Asses Mass Balance And Absolute Bioavailability Of 14C PF-06826647 In Healthy Male Participants

Healthy

Netherlands
Regado Biosciences, Inc.

Completed

Safety, Tolerability and PK/PD of RB006 in a Healthy Volunteer SAD (SC101)

Healthy Volunteer

United States
MedImmune LLC

Completed

Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis

Multiple Sclerosis, Relapsing Forms

United States, Spain, Poland, Ukraine
Acceleron Pharma Inc. (a wholly owned subsidiary...

Terminated

Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

Canada
Human Genome Sciences Inc.
GlaxoSmithKline

Completed

Study of Belimumab Administered Subcutaneously to Healthy Subjects

Healthy

United States
Pfizer

Completed

Effect Of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of PF-06865571 In Subjects With Hepatic Impairment and in Healthy Subjects

Healthy Volunteers | Hepatic Impairment

United States
Pfizer

Completed

Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin

Diabetes Mellitus, Type 2

Taiwan, United States, Hungary, Canada, Slovakia, India, Bulgaria
Pfizer

Completed

A Single Dose Study Of Antimineralocorticoid Activity Of PF-03882845 In Healthy Volunteers

Healthy Volunteers

United States
Adrian Hernandez
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Oral Iron Repletion Effects On Oxygen Uptake in Heart Failure (IRONOUT)

Chronic Heart Failure

United States
Pfizer

Completed

Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects

Skin Diseases | Immune System Diseases | Hypersensitivity | Hypersensitivity, Immediate | Genetic Diseases, Inborn | Skin Diseases, Genetic | Dermatitis | Eczema | Skin Diseases, Eczematous | Dermatitis, Atopic

United States, Spain, Taiwan, Germany, Canada, China, Poland, Belgium, Serbia, Brazil, Russian Federation, Israel, Latvia, Italy, Romania, Mexico, Argentina, Bulgaria, Chile, Netherlands, Slovakia
Abbisko Therapeutics Co, Ltd

Recruiting

A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab in HCC Patients

Hepatocellular Carcinoma

China
Betta Pharmaceuticals Co., Ltd.

Not yet recruiting

Study of MCLA-129 Combined With Befotertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGFR Sensitive Mutation

Non-Small Cell Lung Cancer、EGFR Sensitive Mutation

China
Pfizer

Completed

A Clinical Trial To Evaluate PF-05089771 On Its Own And As An Add-On Therapy To Pregabalin (Lyrica) For The Treatment Of Pain Due To Diabetic Peripheral Neuropathy (DPN)

Diabetic Neuropathy, Painful

United States
Pfizer

Completed

Study Evaluating the Mechanism of Action of PF-04965842 Monotherapy for Moderate-to-severe Atopic Dermatitis (JADE MOA)

Atopic Dermatitis

United States, Canada
Pfizer

Completed

Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis (JADE Mono-2)

Dermatitis, Atopic

China, United States, Australia, Poland, Hungary, Korea, Republic of, Germany, Bulgaria, Canada, Czechia, Japan, Latvia, United Kingdom
Pfizer

Completed

Study to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis (JADE Mono-1)

Dermatitis, Atopic

United States, Hungary, Canada, Germany, Australia, Czechia, Poland, United Kingdom
Pfizer

Completed

Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy (JADE Compare)

Skin Diseases | Immune System Diseases | Hypersensitivity | Hypersensitivity, Immediate | Genetic Diseases, Inborn | Skin Diseases, Genetic | Dermatitis | Eczema | Skin Diseases, Eczematous | Dermatitis, Atopic

Spain, Taiwan, United States, Australia, Poland, Germany, Hungary, Bulgaria, Czechia, Japan, Korea, Republic of, Latvia, Canada, United Kingdom, Mexico, Chile, Slovakia, Italy
Pfizer

Completed

Study of Safety and Efficacy of PF-04991532 in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Taiwan, Slovakia, Mexico, Canada, Hungary
Pfizer

Completed

Study Of Safety And Efficacy Of PF-04991532 In Subjects With Type 2 Diabetes Mellitus

Diabetes, Type 2

Canada, United States, Korea, Republic of, Taiwan, Mexico, Hungary, Slovakia
AbbVie
Boehringer Ingelheim

Completed

A Long Term Extension Trial of BI 655066/ABBV-066 (Risankizumab), in Patients With Moderately to Severely Active Crohn's Disease

Crohn Disease

United States, Belgium, Canada, Germany, Korea, Republic of, Netherlands, Poland, Spain, United Kingdom
Pfizer

Terminated

A Study of the Safety, Tolerability, Pharmacokinetics, And Effects On Histamine-Induced Wheal Of PF-05180999 In Healthy Adults

Migraine

United States
PhaseBio Pharmaceuticals Inc.

Completed

Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM

Type 2 Diabetes Mellitus

United States
Human Genome Sciences Inc.
GlaxoSmithKline

Terminated

Phase 2 Study of Belimumab Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus

United States, Mexico
Amgen

Completed

Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous (IV) Bisphosphonates

Bone Metastases in Men With Hormone-Refractory Prostate Cancer | Bone Metastases in Subjects With Advanced Breast Cancer | Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma
Gruppo Oncologico Italiano di Ricerca Clinica
Mipharm SpA; Temas srl; Clirest s.r.l.; University Hospital of Parma: Department... and other collaborators

Unknown

Biomarker Study of Immune-mediated Mechanism of Action of Neoadjuvant Trastuzumab in HER2+ Breast Cancer Patients (IMMUN-HER)

Cancer, Breast

Italy
University Health Network, Toronto
Gilead Sciences

Active, not recruiting

Lung Transplant HCV, Pilot Study

Hepatitis C | Lung Transplant Infection

Canada
Laboratorios Sophia S.A de C.V.

Completed

Safety and Tolerability of PRO-087 Versus Xyel Ofteno® and Systane Ultra®, on the Ocular Surface of Healthy Subjects (PRO-087/I)

Dry Eye Syndromes | Lubricant Allergy | Tear Disorder

Mexico
Mutual Pharmaceutical Company, Inc.

Completed

Fed Bioavailability Study of Zonisamide Capsules

Healthy

United States
Impax Laboratories, LLC

Completed

A Study to Assess the PK and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson's Disease

Parkinson's Disease

United States
National Taiwan University Hospital
National Science Council, Taiwan

Unknown

Entecavir and Pegasys Sequential Therapy Versus Pegasys for HBeAg Negative Chronic Hepatitis B

Hepatitis B, Chronic

Taiwan
Pfizer

Completed

A Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Oral Doses Of PF-03716539 In Healthy Adult Subjects

Healthy Volunteers

Belgium

Search clinical trials for: Chronic- PF-06480605 150 mg SC Q4W

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Algeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations